# An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

> **NCT02326298** · PHASE3 · COMPLETED · sponsor: **UCB Biopharma S.P.R.L.** · enrollment: 234 (actual)

## Conditions studied

- Psoriasis
- Plaque Psoriasis

## Interventions

- **BIOLOGICAL:** Certolizumab Pegol
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02326298
- **Lead sponsor:** UCB Biopharma S.P.R.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-16
- **Primary completion:** 2016-03-08
- **Final completion:** 2018-10-24
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2019-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02326298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02326298, "An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02326298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*